Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 85 | 特発性間質性肺炎 | 1 |
85. 特発性間質性肺炎
臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04233814 (ClinicalTrials.gov) | January 20, 2020 | 12/1/2020 | Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects | A Randomized, Double-Blind, Placebo-Controlled, Ph 1a, First-in-Man, Single Ascending Dose & Multiple Ascending Dose Safety, Tolerability and PK Study of a Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Healthy Adult Subjects | Idiopathic Pulmonary Fibrosis | Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03);Drug: Placebo | Lung Therapeutics, Inc | NULL | Completed | 18 Years | 55 Years | All | 71 | Phase 1 | United Kingdom |